Traditional Medicine Shows Promise Against Chemotherapy-Induced Nausea in Phase III Trial

Introduction: Could Traditional Formulations Revolutionize CINV Management?

Huo Xiang Zheng Qi Oral Liquid shows significant benefit in preventing chemotherapy-induced nausea and vomiting, according to a newly completed phase III clinical trial. The multicenter study conducted across ten cancer centers in western China demonstrated that adding the traditional Chinese medicine formulation to standard antiemetics substantially improved complete control rates and increased the number of nausea-free days for patients receiving highly emetogenic chemotherapy.

The randomized, placebo-controlled trial enrolled 166 patients undergoing three-day cisplatin-based chemotherapy regimens, with 139 completing the full study protocol. Results showed that patients receiving HXZQ oral liquid in combination with dexamethasone and 5-HT3 receptor antagonists experienced significantly better prevention of chemotherapy-induced nausea and vomiting (CINV) throughout the entire treatment cycle compared to those receiving standard care with placebo.

What Clinical and Regulatory Challenges Does the Study Address?

Despite advances in cancer treatment, CINV remains a persistent challenge that significantly impacts patient quality of life during chemotherapy. Current guidelines from organizations like ASCO and NCCN recommend triple therapy with dexamethasone, 5-HT3 receptor antagonists, and NK-1 receptor antagonists for highly emetogenic chemotherapy. However, real-world implementation of these recommendations remains suboptimal, particularly due to accessibility and cost issues associated with NK-1 receptor antagonists in certain regions.

"This study addresses an important gap in CINV management for patients without access to NK-1 receptor antagonists," the researchers noted in their publication. The trial's primary endpoints focused on mean "No CINV Days" (NCDs) and the complete control rate of CINV beyond the traditional risk period. Patients in the HXZQ group experienced 17.92 NCDs during the full cycle, significantly higher than the 15.26 days observed in the control group (p=0.002). The complete control rate beyond the risk period reached 80.8% in the HXZQ group compared to 60.6% in the control group (p=0.009).

The study also assessed patient quality of life using the Functional Living Index-Emesis (FLIE) questionnaire. By day 21, the HXZQ group demonstrated significantly better functional scores (120.16 vs. 115.00, p=0.047), indicating improved daily functioning and reduced impact of nausea and vomiting on patients' lives. Importantly, no significant safety concerns were identified during the trial, with adverse event profiles comparable between groups.

How Do Herbal Components Contribute to Its Mechanism of Action?

HXZQ Oral Liquid contains extracts of ten herbs, including Atractylodes macrocephala, Orange peel, Magnolia officinalis, and Poria Tuckahoe. According to traditional Chinese medicine principles, the formulation is believed to dispel exterior pathogens, resolve dampness, and regulate qi flow to harmonize the middle burner. Modern pharmacological research suggests that active compounds in HXZQ may work through multiple mechanisms, including anti-inflammatory effects, modulation of serotonergic pathways, and regulation of gastrointestinal motility.

The researchers explained that several bioactive components in HXZQ have demonstrated relevant pharmacological effects in preclinical studies. For example, quercetin (GHX06) has shown significant anti-inflammatory properties by downregulating pro-inflammatory mediators like TNF-α and IL-1β. Other compounds like betulin (DFP01) promote intestinal peristalsis and enhance gastrointestinal motility, while Chuan Chenpianin (CP03) interacts with ion channels in smooth muscle cells to regulate gastrointestinal function.

What Do Preclinical and Clinical Data Tell Us About Efficacy?

Recent preclinical findings provide additional support for HXZQ's efficacy. In a Clostridioides difficile-induced colitis model, the formulation significantly improved survival, reduced intestinal inflammation, and restored microbial homeostasis with efficacy comparable to vancomycin treatment. This suggests that beyond neurotransmitter modulation, HXZQ may also exert protective effects through anti-inflammatory and microbiota-stabilizing pathways.

The study also revealed notable improvements in nausea control specifically, with the HXZQ group experiencing significantly more "No Nausea Days" during the full cycle (18.26 vs. 15.45, p=0.001). This benefit extended to both the traditional risk period and beyond, addressing one of the most challenging aspects of chemotherapy-induced symptoms that conventional antiemetics often fail to adequately control.

How Does This Study Fit Into the Evolving Landscape of Supportive Cancer Care?

The study follows growing interest in traditional Chinese medicine as complementary approaches in supportive oncology. Previous research has explored herbal medicines including astragalus polysaccharide, ginger powder, Hezhong granules, and Rikkunshito for CINV management, with varying degrees of success. This trial represents one of the more rigorous evaluations of a TCM formulation for this specific indication.

The investigators acknowledged several limitations, including the moderate sample size, assessment of only one chemotherapy cycle, and the study's focus on patients without access to NK-1 receptor antagonists. They outlined plans for subsequent research with larger cohorts, investigation of long-term efficacy over multiple chemotherapy cycles, and exploration of HXZQ in combination with NK-1 receptor antagonists.

This study aligns with broader industry trends toward integrating evidence-based traditional medicine into conventional cancer care. As healthcare systems globally seek cost-effective supportive care strategies that improve patient quality of life during treatment, approaches that combine established antiemetics with complementary therapies represent an area of growing interest for both clinical practice and pharmaceutical development.

Summary

A phase III clinical trial conducted across ten cancer centers in western China has demonstrated that Huo Xiang Zheng Qi Oral Liquid (HXZQ), a traditional Chinese medicine formulation, significantly improves the prevention of chemotherapy-induced nausea and vomiting (CINV) when added to standard antiemetic therapy. The randomized, placebo-controlled study enrolled 166 patients undergoing highly emetogenic cisplatin-based chemotherapy, with 139 completing the protocol. Patients receiving HXZQ in combination with dexamethasone and 5-HT3 receptor antagonists experienced substantially more nausea-free days (17.92 versus 15.26 days, p=0.002) and achieved higher complete control rates beyond the traditional risk period (80.8% versus 60.6%, p=0.009) compared to the control group receiving standard care with placebo. The HXZQ group also demonstrated significantly better quality of life scores as measured by the Functional Living Index-Emesis questionnaire, with no significant safety concerns identified. The formulation contains extracts of ten herbs and is believed to work through multiple mechanisms including anti-inflammatory effects, modulation of serotonergic pathways, and regulation of gastrointestinal motility. Preclinical studies have shown that bioactive components such as quercetin exhibit anti-inflammatory properties, while compounds like betulin enhance gastrointestinal motility. The study addresses an important gap in CINV management for patients without access to NK-1 receptor antagonists, which remain cost-prohibitive in certain regions despite being recommended in international guidelines. This research represents one of the more rigorous evaluations of a traditional Chinese medicine formulation for CINV and aligns with growing interest in integrating evidence-based complementary approaches into supportive cancer care.